Skip to content
Kanyos Bio logo — company profile

Kanyos Bio

Founded 2015 United States Cambridge, United States 1 employees Venture round Total: $26.80M Biotechnology, Health Care +1

General Information

Company Name Kanyos Bio
Founded Year 2015
Location United States Cambridge, United States
Employees 1
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Kanyos Bio. To contact Kanyos Bio, visit kanyos.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kanyos Bio compare?

A PDF of Kanyos Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kanyos Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kanyos Bio

Kanyos Bio, founded in 2015, focuses on developing antigen-specific immune tolerance technology for type-1 diabetes and celiac disease. The company, headquartered in the United States, originated from EPFL in Switzerland in collaboration with its sister company, Anokion. Kanyos aims to leverage Anokion's immunotechnology expertise and Astellas Pharma's clinical translation experience to develop disease-modifying therapies. The latest funding of $16.40M was obtained through a Venture Round investment on 12 June 2015, with participation from Novartis Venture Fund and Novo Ventures. This unique approach and strong backing from prominent investors position Kanyos Bio as an innovative player in the biotechnology and healthcare industries.

Business keywords: Antigen-specific immune tolerance technology, Autoimmune indications, Type-1 diabetes, Celiac disease, EPFL, Anokion, Immunotechnology expertise, Clinical translation, Astellas Pharma, Therapies, Disease-modifying, Switzerland, Research and development, Healthcare innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $16.40M 2
Novartis Venture Fund, Novo Ventures
12 Jun 2015
Venture Round $10.40M -
29 May 2015

Kanyos Bio Alternatives & Competitors

View All Alternatives
Kanyos Bio vs
Apitope
Apitope Belgium

Develops drugs for treatments of allergic diseases

Series B
1 employees
Biotechnology, Health Care
Kanyos Bio vs

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary na...

Series A
Biotechnology, Health Care
Kanyos Bio vs

Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discove...

Venture round
Biotechnology, Health Care

FAQ About Kanyos Bio

Kanyos Bio was founded with the goal of developing antigen-specific immune tolerance technology for two specific autoimmune indications, type-1 diabetes and celiac disease. Our technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland with our sister company, Anokion. K...
Kanyos Bio was founded in 2015.
Kanyos Bio is headquartered in Cambridge, United States.
Kanyos Bio operates in Biotechnology, Health Care and Life Sciences. Its work centres on Antigen-specific immune tolerance technology, Autoimmune indications, Type-1 diabetes and Celiac disease.
Kanyos Bio has approximately 1 employees.
Kanyos Bio has completed 2 funding rounds, raising a total of $26.80M. The latest funding stage is Venture round.
Top alternatives and competitors to Kanyos Bio include Apitope, AnTolRx, ImmuneWorks, ImmusanT, VBL Therapeutics (Nasdaq:VBLT). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kanyos Bio and Apitope are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kanyos Bio, https://bouncewatch.com/company/kanyos-bio, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout